Gland Pharma’s Q1 FY27 net profit grew 47% YoY to ₹317 crore, despite a 14% sequential decline. Revenue rose 20% YoY to ₹1,800 crore, driven by CDMO and B2B businesses, with strong contributions from the US and Europe markets.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.